Overview
In 2016, Julia Vitarello’s daughter Mila was diagnosed with a rare, fatal genetic condition caused by a unique mutation in the MEF2C gene. Determined to save her child, Vitarello spearheaded the creation of a personalized, mutation-specific therapy—a one-of-a-kind antisense oligonucleotide (ASO) nicknamed “Mila’s medicine.” This treatment was a landmark in precision medicine, demonstrating that a drug could be designed for a single patient. Yet the path from one bespoke drug to a scalable biotech is fraught with challenges. Vitarello’s first venture, EveryONE Medicines, collapsed when the FDA’s draft guidance on individualized therapies failed to provide the regulatory clarity investors demanded. Now she is starting a new company to accelerate the production of such therapies at scale. This guide takes you through the core concepts, steps, pitfalls, and lessons learned from Mila’s case, offering a roadmap for researchers, entrepreneurs, and patient advocates who want to turn one-off cures into a replicable system.
Prerequisites
Before diving into the step-by-step process for building a platform that makes bespoke genetic therapies scalable, you should understand:
- Basic molecular biology: How DNA mutations affect protein function, and the role of antisense oligonucleotides (ASOs) in modulating RNA splicing or degradation.
- Regulatory landscape: Familiarity with FDA guidance on individualized therapies (e.g., draft guidance released in 2021) and the concept of “n-of-1” trials.
- Business of biotech: Early-stage funding, investor expectations, and the tension between scientific promise and commercial viability.
- Patient advocacy: How motivated families can drive research, as seen in Mila’s story.
Step-by-Step Instructions: Building a Scalable Bespoke Therapy Platform
Step 1: Identify a Proof-of-Concept Model
Start with a single, well-characterized case—like Mila’s. A successful n-of-1 therapy proves that the technology works. Document every step: mutation identification (whole-genome sequencing), ASO design (targeting a cryptic splice site), preclinical testing in patient-derived cells, and compassionate-use approval. For Mila’s medicine, the team demonstrated measurable clinical improvement—reduced seizures and increased developmental gains. This case study becomes the foundation for pitching scalability.
Step 2: Develop a Platform for Rapid ASO Design
Bespoke therapies can’t be designed by hand each time. Build a computational pipeline that automates the identification of actionable mutations and designs ASOs. Key elements:
- Input: patient’s genetic data (VCF file), ideally from a certified lab.
- Algorithm: filters for loss-of-function or gain-of-toxic-function mutations that can be addressed by altering splicing (e.g., skipping an exon, masking a cryptic splice site).
- Output: a shortlist of candidate ASOs with predicted binding energy, off-target scores, and manufacturing feasibility.
Example code snippet (Python pseudo-code for a filtering step):
def identify_actionable_mutations(vcf):
for variant in vcf:
if variant.is_lof and variant.gene in splicing_regulation:
return design_aso(variant)
else:
continue
Step 3: Establish a Lean Preclinical Pipeline
Each new ASO must be tested for safety and efficacy. Create a standardized in vitro assay using patient-derived fibroblasts or iPSCs (induced pluripotent stem cells). For Mila’s drug, the team used primary cells to show corrected RNA splicing. A scalable pipeline requires:
- Cell line repository: Collect and bank cells from patients with rare mutations.
- High-throughput screening: Use qPCR or RNA-seq to measure target engagement.
- Toxicity screening: Off-target predictions and cell viability tests.
Automation reduces the turnaround from months to weeks.
Step 4: Navigate the Regulatory Maze
The FDA’s 2021 draft guidance on individualized ASOs was a double-edged sword. It encouraged development but stopped short of creating a standardized NDA (New Drug Application) pathway for therapies that change with each patient. For a scalable company, you need a strategy:
- Apply for Rare Pediatric Disease Designation (if applicable) to get a priority review voucher.
- Use the Expanded Access (Compassionate Use) pathway for early patients while simultaneously collecting data for an eventual IND (Investigational New Drug).
- Advocate for a “platform approval” where the FDA approves the process rather than each individual molecule. Vitarello’s new company plans to lobby for this change.
Step 5: Secure Funding with a Realistic Timeline
Investors consider bespoke therapies high-risk, low-reward without a clear path to profit. EveryONE Medicines failed because investors wanted a faster return than the FDA could provide. To attract funders:
- Show a validated platform with multiple successful n-of-1 cases.
- Project a pipeline of 10–20 patients per year with a cost per therapy that can be reduced over time.
- Seek non-dilutive grants (NIH, CZI, patient foundations) to de-risk early development.
- Propose a subscription model or outcome-based pricing for insurers.
Step 6: Build a Collaborative Ecosystem
No single entity can do it all. Partner with:
- Academic labs: for mutation discovery and functional validation.
- CDMOs (Contract Development and Manufacturing Organizations): for GMP-grade ASO synthesis.
- Patient advocacy groups: for recruitment and funding.
- Regulatory consultants: to craft a communication strategy with the FDA.
Vitarello’s new venture is leveraging relationships built during Mila’s journey to create a coalition of scientists and investors.
Common Mistakes
Mistake 1: Overpromising on Turnaround Time
Developing a bespoke ASO from mutation identification to patient dosing can take 6–12 months. Investors and families may expect weeks. Set realistic expectations and communicate the steps: sequencing (2 weeks), ASO design (1 week), preclinical testing (4–8 weeks), regulatory approval (variable), manufacturing (4 weeks). Mila’s first dose came 9 months after diagnosis.
Mistake 2: Ignoring Off-Target Effects
Each ASO is unique; off-target predictions based on sequence similarity may miss real-world toxicities. Always perform in vitro toxicity panels and consider neurological safety if the ASO crosses the blood-brain barrier (Mila’s medicine was delivered intrathecally). A scalable platform must include a safety module that flags high-risk sequences.
Mistake 3: Assuming One Regulatory Path Works for All
The FDA treats each n-of-1 therapy as a separate IND. That means 10 patients = 10 IND submissions. This is unsustainable. Some companies have applied for a master protocol that allows multiple ASOs under one umbrella IND—but the FDA has not yet fully embraced this. Consult early and often with regulators to avoid wasting resources on a flawed strategy.
Mistake 4: Underfunding the Business Side
EveryONE Medicines folded partly because investors lost confidence after the FDA draft guidance didn’t meet their expectations. A scalable biotech needs a sustainable business model, not just scientific enthusiasm. Budget for regulatory consultancy, patient outreach, and long manufacturing lead times. Do not rely solely on donor capital—plan for a revenue stream even if it’s small initially.
Summary
Julia Vitarello’s journey from Mila’s bespoke medicine to a new biotech exemplifies the promise and pitfalls of personalized gene therapies at scale. The path requires a solid proof-of-concept, automated ASO design, a lean preclinical pipeline, creative regulatory navigation, patient funding, and a collaborative ecosystem. Common mistakes include unrealistic timelines, insufficient safety screening, regulatory naïveté, and business undercapitalization. With lessons from EveryONE’s failure, Vitarello’s next venture aims to overcome these barriers by pushing for platform-level FDA approval and building investor confidence through multiple successful cases. For anyone attempting to replicate this model, the key is to combine scientific rigor, patient urgency, and pragmatic business planning.